Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics

This publication has 43 references indexed in Scilit:

• HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
  Cell Death & Disease, 2013
• Advancing toxicology in RiskMAPP: Setting ADEs based on the subsequent drug substance
  Regulatory Toxicology and Pharmacology, 2013
• Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
  Cancer Letters, 2011
• ASHP Guidelines on Handling Hazardous Drugs
  American Journal of Health-System Pharmacy, 2006
• Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy
  Cell Cycle, 2004
• New cancer therapeutics: target-specific in, cytotoxics out?
  Drug Resistance Updates, 2004
• The proteasome: a novel target for cancer chemotherapy
  Leukemia, 2002
• Genotoxicity of several clinically used topoisomerase II inhibitors
  Toxicology Letters, 2000
• Mechanism of action of DNA topoisomerase inhibitors
  Stem Cells, 1995
• The mutagenic activity of razoxane (ICRF 159): An anticancer agent
  British Journal of Cancer, 1985